Category: Uncategorized

CERRITOS, Calif., May 08, 2025 (GLOBE NEWSWIRE) — The Oncology Institute, Inc. (NASDAQ: TOI)(“TOI”), one of the largest value-based oncology groups in the United States, announced today that it has been selected to present an abstract at the upcoming ASCO Annual Meeting further validating cost savings and reduced hospitalizations associated with its unique High-Value Cancer Care (HVCC) model*. The study shares new data supporting prior publications which demonstrate superior outcomes for acute-care patients when enrolled in the TOI HVCC model.

“Without compromising on the clinical outcomes for our oncology patients, TOI has again demonstrated the ability to drive down both Emergency Department utilization and hospitalizations by over 50%, while simultaneously driving over $12,000 in cost savings per patient enrolled,” said Yale Podnos, MD, MPH, FACS, Chief Medical Officer at TOI. “This further validates the power of our care model in both improving clinical outcomes and providing value to our patients and payor partners through our highly coordinated, industry-leading approach to care.”

Summary of Outcomes of the Most Recent Clinical Trial Analysis:

• 53% Lower Emergency Department Use
• 68% Lower Hospitalizations
• 75% Lower Odds of Acute Care Facility Death
• Lower Total Cost of Care by $12,000 per Enrolled Patient

*Patel, et al. Improving care of older adults with cancer: A randomized trial. ASCO Annual Meeting Health Services Section, May 30, 2025.

About The Oncology Institute

Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of over 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With over 120 employed clinicians and more than 700 teammates in over 70 clinic locations, TOI is changing oncology for the better.

For more information, visit 

www.theoncologyinstitute.com

Contacts

Media

The Oncology Institute, Inc.


[email protected]

Investors

Solebury Strategic Communications


[email protected]

FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world’s leading supplier of microinverter-based solar and battery systems, today announced the availability of new software that allows homeowners with existing legacy IQ7™ Microinverter-based systems to seamlessly expand their solar capacity using IQ8™ Microinverters. This software is now available across North America, Europe, and other key markets.

With over one million homes worldwide using IQ7™ Microinverters, many homeowners are now looking to expand their systems to reduce energy costs and boost energy independence. Enphase’s new software enables solar installers to upgrade these systems with IQ8™ Microinverters, built for high-powered solar panels, while using the existing IQ^® Gateway or IQ^® Combiner hardware.

“Enphase’s new expansion capability with the IQ8 Microinverters is a game-changer for us,” said Jeremy White, project manager at Robco Electric, an installer of Enphase products in the United States. “It allows us to offer our customers a straightforward path to scale their systems as their energy needs grow. We can now deliver more power with fewer headaches, which helps us provide the best service and keeps our business running efficiently.”

“Homeowners are increasingly asking for ways to get more out of their existing systems, and the new IQ8 Microinverters make that possible,” said Mauricio Llovera, CEO of INVERSOL, an installer of Enphase products in Mexico. “This solution is a win-win, as it not only benefits our customers but also enables us to take on more projects without the complexity of traditional system upgrades. It’s the kind of innovation we’ve come to expect from Enphase.”

“We’re excited to see Enphase continue to build on its existing product suite, constantly making our lives easier,” said David Monnier, CEO of La Maison des Energies, an installer of Enphase products in Switzerland. “The IQ8 Microinverters provide a seamless integration experience, allowing us to maximize energy output for our customers while maintaining the reliability and quality Enphase is known for. This capability is a significant boost to our business.”

“The ability to upgrade existing IQ7 systems with IQ8 Microinverters opens up new opportunities for homeowners in the Netherlands,” said Jack van der Linden, account manager at Green Guys BV, an installer of Enphase products in the Netherlands. “With energy prices fluctuating, our customers want to optimize their solar systems without costly overhauls. This new solution from Enphase allows them to do just that — scaling their energy production efficiently and cost-effectively.”

“Enphase’s latest innovation simplifies system upgrades for our customers in France, making it easier than ever to enhance solar production,” said Julien Vouriot, CEO and founder of Solair’ Forez, an installer of Enphase products in France. “We can now provide homeowners with a seamless way to integrate the latest microinverter technology, ensuring they get the most out of their solar investments while maintaining system reliability.”

“The new software release unlocks seamless interoperability between IQ7 and IQ8 microinverters, which empowers our global installer network to deliver more value with less effort,” said Aaron Gordon, senior vice president and general manager of the systems business unit at Enphase Energy. “It’s a win for homeowners and a growth driver for our installers.”

Enphase’s software-defined energy systems allow homeowners the ability to scale and optimize their solar investments over time. For more information about adding IQ8 Microinverters to IQ7 systems, watch the video here and visit the regional websites — United States, France, Switzerland, the Netherlands, and Germany.

About Enphase Energy, Inc.

Enphase Energy, a global energy technology company based in Fremont, CA, is the world’s leading supplier of microinverter-based solar and battery systems that enable people to harness the sun to make, use, save, and sell their own power — and control it all with a smart mobile app. The company revolutionized the solar industry with its microinverter-based technology and builds all-in-one solar, battery, and software solutions. Enphase has shipped approximately 81.5 million microinverters, and approximately 4.8 million Enphase-based systems have been deployed in over 160 countries. For more information, visit https://enphase.com/.

©2025 Enphase Energy, Inc. All rights reserved. Enphase Energy, Enphase, the “e” logo, IQ, and certain other marks listed at https://enphase.com/trademark-usage-guidelines are trademarks or service marks of Enphase Energy, Inc. in the U.S. and other countries. Other names are for informational purposes and may be trademarks of their respective owners.

Forward-Looking Statements

This press release may contain forward-looking statements, including statements related to the expected capabilities and performance of Enphase Energy’s technology and products, including safety, quality, and reliability; and the ability to continually enhance and maximize the value of their investments over the lifetime of the systems. These forward-looking statements are based on Enphase Energy’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties including those risks described in more detail in Enphase Energy’s most recently filed Quarterly Report on Form 10-Q, Annual Report on Form 10-K, and other documents filed by Enphase Energy from time to time with the SEC. Enphase Energy undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations, except as required by law.

Contact:

Enphase Energy

[email protected]

This press release was published by a CLEAR® Verified individual.

ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) — Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that Alzamend’s board of directors approved a one-for-nine reverse stock split of Alzamend’s common stock (“Common Stock”) that will be effective in the State of Delaware at 12:01 a.m. Eastern Time on May 12, 2025. Beginning with the opening of trading on May 12, 2025, the Company’s Common Stock will trade on The Nasdaq Capital Market on a split-adjusted basis under the Company’s existing trading symbol “ALZN”. The new CUSIP number for the Common Stock will be 02262M605. The reverse stock split is part of the Company’s plan to maintain compliance with the minimum bid price requirement of $1.00 per share required to maintain continued listing on The Nasdaq Capital Market, among other benefits.

The reverse stock split affects all issued and outstanding shares of the Company’s Common Stock, as well as the number of shares of Common Stock available for issuance under the Company’s equity incentive plans. In addition, the reverse stock split reduces the number of shares of Common Stock issuable upon the exercise of stock options or warrants outstanding immediately prior to the reverse split. The par value of the Company’s Common Stock will remain unchanged at $0.0001 per share after the reverse stock split. The reverse stock split affects all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s equity, except to the extent that the reverse stock split results in some stockholders owning a fractional share. No fractional shares will be issued in connection with the reverse split. Stockholders who would otherwise be entitled to receive a fractional share will instead receive a cash payment. As of the date of this press release, Alzamend has 7,208,591 shares of Common Stock issued and outstanding, which it anticipates will result in approximately 800,954 shares of Common Stock after the reverse stock split is effective.

Computershare Trust Company, N.A. (“Computershare”), is acting as the exchange agent and transfer agent for the reverse stock split. Computershare will provide instructions to stockholders for receiving payment for any fractional shares.

About Alzamend Neuro

Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BD, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 – a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, salicylate and L-proline, and ALZN002 – a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s by removing beta-amyloid from the brain. The latter is a second-generation active-immunity approach designed to mitigate the disadvantages of approved passive immunity marketed antibody products, particularly by reducing the required frequency and costs of dosing associated with antibody products. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and Alzamend undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect Alzamend’s business and financial results are included in Alzamend’s filings with the U.S. Securities and Exchange Commission. All filings are available at www.sec.gov and on Alzamend’s website at www.Alzamend.com.

Contacts:


Email: [email protected] or call: 1-844-722-6333

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from eight presentations at the European Association for the Study of the Liver (EASL) Congress 2025, being held May 7 – 10, 2025 in Amsterdam, Netherlands.

“We are pleased to have eight presentations at this year’s EASL Congress from programs across our pipeline,” stated Lawrence Blatt, PhD, MBA, Chairman, President, & CEO of Aligos Therapeutics. “In particular, we are excited to share an update on the 96-week data from the monotherapy cohort receiving 300 mg ALG-000184. All subjects in both the HBeAg⁺ and HBeAg^– cohorts have achieved HBV DNA viral suppression < LLOQ (10 IU/mL) and continue to demonstrate sustained log₁₀ reductions in viral antigens such as HBcrAg. These data further strengthen our belief that ALG-000184 is a first-/best-in-class asset with the potential to improve patient outcomes. Additionally, we will present biomarker and subgroup analyses from the Phase 2a HERALD study. These data continue to demonstrate the best-in-class potential of ALG-055009 across the cardio-metabolic space.”

Two presentations highlight the continued potent antiviral activity of ALG-000184 for chronic hepatitis B virus (HBV) infection in both untreated HBeAg⁺ and HBeAg^– subjects, demonstrating the potential for the molecule to become first-line therapy for chronic suppression and the backbone for regimens aimed at functional cure.

In HBeAg⁺ subjects with a very high mean HBV DNA level of 8.0 log₁₀ IU/mL at baseline, all experienced profound and persistent HBV DNA reductions after receiving an oral daily dose of 300 mg ALG-000184 monotherapy. At Week 48, 6 of 10 subjects (60%) achieved HBV DNA < LLOQ (10 IU/mL, target detected or target not detected). With treatment extension, this rate increased to 9 of 9 subjects (100%) at Week 96. Additionally, HBV DNA level continuously declined to < LLOQ (target not detected, <4.29 IU/mL) in 5 of 9 subjects at Week 96.

In HBeAg^– subjects, all 11 (100%) had rapid decline in HBV DNA levels and achieved sustained HBV DNA suppression (HBV DNA < LLOQ, target detected or target not detected) by Week 24. The HBV DNA suppression level was maintained in the ALG-000184 monotherapy cohort for up to 96 weeks, with further decline in HBV DNA to < LLOQ, target not detected, observed in all subjects (8/8) at Week 96.

Importantly, no viral breakthrough was observed in any chronic HBV infection subjects receiving ALG-000184 monotherapy for up to 96 weeks. The resistant analysis reported no known CAM resistant mutations had been identified with ALG-000184 monotherapy.   

HBV RNA level achieved < LLOQ (10 copies/mL) in all HBeAg⁺ and HBeAg^– subjects by Week 52 and Week 8, respectively. Furthermore, concurrent multi-log₁₀ reductions in HBV antigens (HBsAg, HBeAg, and HBcrAg) in HBeAg⁺ subjects and HBcrAg decline in HBeAg^– subjects were observed, suggesting the potential inhibition of cccDNA establishment by CAM-E 2^nd mechanism of action of ALG-000184.

A favorable tolerability profile has been demonstrated in untreated HBeAg⁺ and HBeAg^– subjects receiving 300 mg ALG-000184 for up to 96 weeks.

Additionally, two presentations will showcase the best-in-class potential of ALG-055009, a purpose built THR-β agonist discovered by Aligos scientists. As previously presented at AASLD’s The Liver Meeting in 2024, 12-weeks of once daily ALG-055009 treatment in MASH patients met the primary endpoint, with robust reductions in liver fat content at Week 12. Doses of 0.5 mg to 0.9 mg ALG-055009 demonstrated statistically significant reductions in liver fat at Week 12, with placebo-adjusted median relative reductions up to 46.2% as measured by MRI-PDFF. Eighteen subjects who were on stable GLP-1 agonist therapy qualified for enrollment in the study, with liver fat content meeting the inclusion criteria of ≥10% at baseline as measured by MRI-PDFF. Notably, 11/14 subjects on stable GLP-1 agonists treated with ALG-055009 had liver fat decreases, whereas 4/4 subjects on stable GLP-1 agonists treated with placebo had increases in liver fat over the 12-week dosing period. Treatment with ALG-055009 was well-tolerated, with rates of gastrointestinal-related AEs similar to placebo.

New data being presented at the EASL congress will demonstrate substantial, dose-dependent reductions in liver fat were observed across all key subgroups with 12 weeks of once daily ALG-055009 treatment. In addition, statistically significant improvements in atherogenic lipids were achieved with 12 weeks of ALG-055009 treatment. Reductions in lipids/lipoproteins were observed even in the context of stable GLP-1 agonist or statin use. This data suggests an added benefit of ALG-055009 for patients at risk for cardiovascular disease in addition to the previously reported liver fat lowering properties in a MASLD/MASH population.

Details of the presentations are as follows:

ALG-000184: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B

 

virus (HBV) infection

Poster #: THU-261
Title: Monotherapy with the Novel Capsid Assembly Modulator ALG-000184 for up to 96 Weeks Results in Profound and Sustained HBV DNA Suppression in Untreated Subjects with Chronic HBV Infection
Presenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong
Date/Time: May 8, 2025 at 4:15pm – 5:00pm CET; May 8, 2025 at 8:30am – 5:00pm CET
Session: Poster Tour; Poster – Viral Hepatitis B and D: New therapies, unapproved therapies or strategies

Poster #: THU-256
Title: The Safety and Antiviral Effect of Oral Daily 300 mg ALG-000184 in Combination with Entecavir for up to 96 Weeks in Untreated HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection
Presenter: Professor Jinlin Hou, MD, Chairman and Professor of the Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University
Date/Time: May 8, 2025 at 8:30am – 5:00pm CET
Session: Poster – Viral Hepatitis B and D: New therapies, unapproved therapies or strategies

Poster #: THU-242
Title: Viral kinetics and sequence analysis of a phase I monotherapy study in subjects with chronic hepatitis B reveals a high barrier of resistance to the capsid assembly modulator ALG-000184
Presenter: Andreas Jekle, PhD
Date/Time: May 8, 2025 at 8:30am – 5:00pm CET
Session: Poster – Viral Hepatitis B and D: New therapies, unapproved therapies or strategies

ALG-055009: Potential best-in-class small molecule THR-


β


for Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Poster #: SAT-451
Title: ALG-055009, a novel thyroid hormone receptor beta agonist, demonstrated significant reductions in atherogenic lipids/lipoproteins, including lipoprotein (a), in patients with presumed metabolic dysfunction-associated steatohepatitis in the Phase 2a HERALD
Presenter: Stanley Wang, MD, PhD
Date/Time: May 8, 2025 at 9:45am – 10:30am CET; May 10, 2025 at 8:30am – 4:00pm CET
Sessions: Poster tour; Poster – MASLD: Therapy

Poster #: SAT-450
Title: ALG-055009, a novel thyroid hormone receptor beta (THR-beta) agonist, demonstrated robust reductions in liver fat at Week 12 across subgroups including glucagon-like peptide-1 (GLP-1) receptor agonist users in non-cirrhotic MASH patients in the Phase 2a HERALD study
Presenter: Megan Fitzgerald, PhD
Date/Time: May 10, 2025 at 8:30am – 4:00pm CET
Session: Poster – MASLD: Therapy

Poster #: SAT-430
Title: Population pharmacokinetic/pharmacodynamic modelling of novel thyroid hormone receptor beta agonist ALG-055009 reveals statistically significant correlation between exposure and key efficacy endpoints
Presenter: Kha Le, PhD
Date/Time: May 10, 2025 at 8:30am – 4:00pm CET
Session: Poster – MASLD: Therapy

Poster #: FRI-450
Title: ALG-055009, a potent and selective thyroid hormone receptor beta agonist for the treatment of metabolic dysfunction-associated steatohepatitis, induces pro-metabolic and anti-fibrotic gene expression in the liver of diet-induced obese mice
Presenter: Xuan Luong, PhD
Date/Time: May 9, 2025 at 8:30am – 5:00pm CET
Session: Poster – MASLD: Experimental and pathophysiology

Preclinical

Poster #: FRI-257
Title: Next generation hepatitis B virus antisense oligonucleotides incorporating novel chemistries demonstrated significantly improved properties compared to current clinical candidates
Presenter: Jin Hong, PhD
Date/Time: May 9, 2025 at 8:30am – 5:00pm CET
Session: Poster – Viral Hepatitis: Experimental and pathophysiology

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.

For more information, please visit www.aligos.com or follow us on LinkedIn or X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.  

Investor Contact

Aligos Therapeutics, Inc.
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
[email protected]

Media Contact

Inizio Evoke
Jake Robison
Vice President
[email protected]

BOCA RATON, Fla., May 08, 2025 (GLOBE NEWSWIRE) — FOREWARN, LLC, a red violet company (NASDAQ: RDVT) and the leading provider of real-time information solutions for real estate agents, today announced that NEXUS Association of REALTORS^® (“NEXUS”) will offer FOREWARN^® services to its 5,000+ members it serves throughout Burlington, Camden, and Ocean counties to promote proactive real estate agent safety.

Available both online and through a mobile application, FOREWARN analyzes billions of data points and provides users with the ability to mitigate risks by verifying identity, searching for criminal histories, and validating information provided by potential clients — using just a phone number. FOREWARN allows agents to properly and safely plan for showings with a higher level of confidence.

The FOREWARN services offered by NEXUS are available to the 5,000+ members at no additional cost to individual agents.

“Ensuring our members have the tools to work safely and confidently is a top priority,” stated Vernon Jones III, CEO of NEXUS Association of REALTORS^®. “By providing FOREWARN, we are taking a proactive step in protecting our members from potential risks. The ability to instantly verify identities enhances both security and peace of mind in every interaction.”

Existing NEXUS members will receive specific instructions on how to move forward with activating their FOREWARN subscription as an included benefit.

All other real estate agencies, agents, and appraisers can learn more about FOREWARN at www.forewarn.com.

About FOREWARN^®

At FOREWARN, we bring instant knowledge through innovative solutions to ensure safer engagements and smarter interactions. Leveraging powerful analytics and a massive data repository, our solutions enable organizations to gain real-time knowledge, for purposes such as verifying identity, searching for criminal histories, and validating information. Risk assessment and due diligence at your fingertips™.

RELATED LINKS:

www.forewarn.com

About red violet^®

At red violet, we build proprietary technologies and apply analytical capabilities to deliver identity intelligence. Our technology powers critical solutions, which empower organizations to operate with confidence. Our solutions enable the real-time identification and location of people, businesses, assets and their interrelationships. These solutions are used for purposes including identity verification, risk mitigation, due diligence, fraud detection and prevention, regulatory compliance, and customer acquisition. Our intelligent platform, CORE™, is purpose-built for the enterprise, yet flexible enough for organizations of all sizes, bringing clarity to massive datasets by transforming data into intelligence. Our solutions are used today to enable frictionless commerce, to ensure safety, and to reduce fraud and the concomitant expense borne by society. For more information, please visit www.redviolet.com.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipate,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning. Such forward looking statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations, including whether FOREWARN will address critical safety and security areas for NEXUS Association of REALTORS® members and whether FOREWARN will protect NEXUS Association of REALTORS® members from potential risks and give them peace of mind in every interaction. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release and are advised to consider the factors listed above together with the additional factors under the heading “Forward-Looking Statements” and “Risk Factors” in red violet’s SEC Filings. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations Contact:

Camilo Ramirez
Red Violet, Inc.
561-757-4500
[email protected]

MONTREAL, May 08, 2025 (GLOBE NEWSWIRE) — D-BOX Technologies Inc. (“D-BOX” or the “Corporation”) (TSX: DBO), a Corporation with more than 25 years of experience creating haptic and immersive experiences, is proud to announce an expansion of its long-standing relationship with Cinemark Holdings, Inc. (“Cinemark”), one of the largest and most influential theatrical exhibition companies in the world.

This rollout will add over 70 D-BOX haptic-enabled screens across as many as 25 Cinemark theaters in the United States in the next eighteen (18) months, predominately in theaters that have yet to experience D-BOX. This expansion represents a significant investment and marks one of the largest multi-site expansions of D-BOX screens in recent years. Notably, the expansion will increase Cinemark’s worldwide D-BOX presence to more than 500 auditoriums, further solidifying its position as the exhibitor with the highest D-BOX penetration.

“This continued collaboration with Cinemark highlights a shared commitment to innovation and premium experiences,” said Sébastien Mailhot, President and CEO of D-BOX. “The fact that Cinemark is not only opening new D-BOX locations but also expanding existing ones shows the strength of the format and the growing audience appetite for immersive entertainment.”

This latest expansion underscores D-BOX’s ongoing commitment to redefining theatrical entertainment through innovation. By extending its immersive haptic technology to more locations in the United States, D-BOX is not only growing its global presence but also helping exhibitors deliver differentiated experiences that drive audience engagement and change the way they interact with films.

ABOUT CINEMARK HOLDINGS, INC.

Cinemark Holdings, Inc. (NYSE: CNK) provides extraordinary out-of-home entertainment experiences as one of the largest and most influential theatrical exhibition companies in the world. Based in Plano, Texas, Cinemark makes every day cinematic for moviegoers across nearly 500 theaters and more than 5,500 screens, operating in 42 states in the U.S. (304 theaters; 4,255 screens) and 13 South and Central American countries (193 theaters; 1,398 screens). Cinemark offers guests superior sight and sound technology, including Barco laser projection and Cinemark XD, the world’s No. 1 exhibitor-branded premium large format; industry-leading penetration of upscale amenities such as expanded food and beverage offerings, Luxury Lounger recliners and D-BOX motion seats; top-notch guest service; and award-winning loyalty programs such as Cinemark Movie Club. All of this creates an immersive environment for a shared, entertaining escape, underscoring that there is no place more cinematic than Cinemark. For more information, visit https://ir.cinemark.com.

ABOUT D-BOX

D-BOX creates and redefines realistic, immersive entertainment experiences by moving the body and sparking the imagination through effects: motion, vibration and texture. D-BOX has collaborated with some of the best companies in the world to deliver new ways to enhance great stories. Whether it’s movies, video games, music, relaxation, virtual reality applications, themed entertainment or professional simulation, D-BOX creates a feeling of presence that makes life resonate like never before. D-BOX Technologies Inc. (TSX: DBO) is headquartered in Montreal with offices in Los Angeles, USA and Beijing, China. Visit D BOX.com

FOR FURTHER INFORMATION, PLEASE CONTACT:

D-BOX TECHNOLOGIES INC.

Josh Chandler
Chief Financial Officer
D-BOX Technologies Inc.
[email protected]

CINEMARK HOLDINGS, INC.

Caitlin Piper
[email protected]

DISCLAIMER REGARDING FORWARD-LOOKING STATEMENTS

Certain information included in this press release may constitute “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information may include, among others, statements regarding the future plans, activities, objectives, operations, strategy, business outlook, and financial performance and condition of the Corporation, or the assumptions underlying any of the foregoing. In this document, words such as “may”, “would”, “could”, “will”, “likely”, “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate” and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. Forward-looking information, by its very nature, is subject to numerous risks and uncertainties and is based on several assumptions which give rise to the possibility that actual results could differ materially from the Corporation’s expectations expressed in or implied by such forward-looking information and no assurance can be given that any events anticipated by the forward-looking information will transpire or occur, including but not limited to the future plans, activities, objectives, operations, strategy, business outlook and financial performance and condition of the Corporation.

Forward-looking information is provided in this press release for the purpose of giving information about Management’s current expectations and plans and allowing investors and others to get a better understanding of the Corporation’s operating environment. However, readers are cautioned that it may not be appropriate to use such forward-looking information for any other purpose.

Forward-looking information provided in this document is based on information available at the date hereof and/or management’s good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Corporation’s control.

The risks, uncertainties and assumptions that could cause actual results to differ materially from the Corporation’s expectations expressed in or implied by the forward-looking information include, but are not limited to, the ability to complete the rollout within the planned timeframe amidst political and economic uncertainty. These and other risk factors that could cause actual results to differ materially from expectations expressed in or implied by the forward-looking information are discussed under “Risk Factors” in the Corporation’s annual information form for the fiscal year ended March 31, 2024, a copy of which is available on SEDAR+ at www.sedarplus.ca.

Except as may be required by Canadian securities laws, the Corporation does not intend nor does it undertake any obligation to update or revise any forward-looking information contained in this press release to reflect subsequent information, events, circumstances or otherwise.

The Corporation cautions readers that the risks described above are not the only ones that could have an impact on it. Additional risks and uncertainties not currently known to the Corporation or that the Corporation currently deems to be immaterial may also have a material adverse effect on the Corporation’s business, financial condition or results of operations.

BOCA RATON, FL, May 08, 2025 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (“DeFi Dev Corp” or the “Company”), or formally known as Janover Inc. (Nasdaq: JNVR), today announced the closing of its previously announced private investment in public equity (“PIPE”) financing. The PIPE resulted in gross proceeds of approximately $24 million to the Company, before placement agent fees and offering expenses.

Pursuant to the terms of the securities purchase agreement, the Company sold 315,838 shares of its common stock and pre-funded warrants to purchase an aggregate of 207,679 shares of its common stock. The purchase price for the shares of common stock was $46.00 per share and the purchase price for pre-funded warrants was $45.99 per underlying share. Net proceeds are expected to be used for general corporate purposes, including to be deployed toward continued accumulation of Solana (SOL).

The securities described above were sold in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and/or Rule 506(b) of Regulation D promulgated thereunder and have not been registered under the Act or applicable state securities laws. Accordingly, the securities may not be resold absent registration under the Act or an applicable exemption from such registration requirements. Concurrently with the execution of the securities purchase agreement, the Company and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About DeFi Development Corp.

DeFi Development Corp. (Nasdaq: JNVR) has adopted a treasury policy under which the principal holding in its treasury reserve on the balance sheet will be allocated to Solana (SOL). In adopting its new treasury policy, the Company intends to provide investors a way to access the Solana ecosystem. The Company’s treasury policy is expected to provide investors economic exposure to SOL investment.

We are an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions as well as value-add services to multifamily and commercial property professionals as we connect the increasingly complex ecosystem that stakeholders have to manage.

We currently serve more than one million web users annually, including multifamily and commercial property owners and developers applying for billions of dollars of debt financing per year, professional service providers, and thousands of multifamily and commercial property lenders including more than 10% of the banks in America, credit unions, real estate investment trusts (“REITs”), debt funds, Fannie Mae® and Freddie Mac® multifamily lenders, FHA multifamily lenders, commercial mortgage-backed securities (“CMBS”) lenders, Small Business Administration (“SBA”) lenders, and more. Our data and software offerings are generally offered on a subscription basis as software as a service (“SaaS”).

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” strategy,” “future,” “likely,” “may,”, “should,” “will” and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) fluctuations in the market price of SOL and any associated impairment charges that the Company may incur as a result of a decrease in the market price of SOL below the value at which the Company’s SOL are carried on its balance sheet; (ii) the effect of and uncertainties related the ongoing volatility in interest rates; (iii) our ability to achieve and maintain profitability in the future; (iv) the impact on our business of the regulatory environment and complexities with compliance related to such environment including changes in securities laws or other laws or regulations; (v) changes in the accounting treatment relating to the Company’s SOL holdings; (vi) our ability to respond to general economic conditions; (vii) our ability to manage our growth effectively and our expectations regarding the development and expansion of our business; (viii) our ability to access sources of capital, including debt financing and other sources of capital to finance operations and growth and (ix) other risks and uncertainties more fully in the section captioned “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and other reports we file with the SEC. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

Investor Contact:
[email protected]

Media Contact:
Prosek Partners
[email protected]